두경부 편평상피세포암에 대한 최근 약제 개발과 연구 방향

참고문헌 (92)

1. World cancer report 2014, "International Agency for Research on Cancer", International Agency for Research on Cancer, ~ (2014)
2. Benson E, "The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas", Oral Oncol, 50, pp.565~574 (2014)
3. International Cancer Genome Consortium, "International network of cancer genome projects", Nature, 464(7291), pp.993~998 (2010)
4. Agrawal N, "Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1", Science, 333(6046), pp.1154~1157 (2011)
5. Stransky N, "The mutational landscape of head and neck squamous cell carcinoma", Science, 333(6046), pp.1157~1160 (2011)
6. Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517(7536), pp.576~582 (2015)
7. Marur S, "Head and neck cancer : Changing epidemiology, diagnosis, and treatment", Mayo Clin Proc, 83(4), pp.489~501 (2008)
8. Saloura V, "An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinumrefractory squamous cell carcinoma of the head and neck", Cancer Chemother Pharmacol, 73(6), pp.1227~1239 (2014)
9. Blasco MA, "Systemic therapy for head and neck squamous cell carcinoma : Historical perspectives and recent breakthroughs", Laryngoscope, 127(11), pp.2565~2569 (2017)
10. Zumsteg ZS, "Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma : An analysis of the National Cancer Data Base", Cancer, 123(23), pp.4583~4593 (2017)
11. Szabó B, "Clinical significance of genetic alterations and expression of epidermal growth factor receptor(EGFR)in head and neck squamous cell carcinomas", Oral Oncol, 47(6), pp.487~496 (2011)
12. Bonner JA, "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck", N Engl J Med, 354(6), pp.567~578 (2006)
13. National Comprehensive Cancer Network, "NCCN guidelines: Head and neck cancer, version 3 2019", National Comprehensive Cancer Network INC, ~ (2019)
14. Huang J, "Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab : A meta-analysis", BMC Cancer, 16, pp.689~ (2016)
15. Lee YS, "An update : Emerging drugs to treat squamous cell carcinomas of the head and neck", Expert Opin Emerg Drugs, 23(4), pp.283~299 (2018)
16. Leemans CR, "The molecular biology of head and neck cancer", Nat Rev Cancer, 11(1), pp.9~22 (2011)
17. Chung CH, "Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma", Cancer Res, 66(16), pp.8210~8218 (2006)
18. Schneider-Merck T, "Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage", J Immunol, 184(1), pp.512~520 (2010)
19. Bonner JA, "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer : 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival", Lancet Oncol, 11(1), pp.21~28 (2010)
20. Burtness B, "Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic", recurrent head and neck cancer : An Eastern Cooperative Oncology Group study, 2005, pp.23(34), 8646~8654
21. Vermorken JB, "Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, 2007, pp.25(16), 2171~2177
22. Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359(11), pp.1116~1127 (2008)
23. Vermorken JB, "Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck(SPECTRUM) : An open-label phase 3 randomised trial", Lancet Oncol, 14(8), pp.697~710 (2013)
24. Sacco AG, "Molecularly targeted therapy for the treatment of head and neck cancer : A review of the ErbB family inhibitors", Onco Targets Ther, 9, pp.1927~1943 (2016)
25. Cohen EEW, "Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and", or metastatic head and neck cancer, 2017, pp.28(10), 2526~2532
26. Seiwert TY, "A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck", Ann Oncol, 25(9), pp.1813~1820 (2014)
27. Van Allen EM, "Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma", JAMA Oncol, 1(2), pp.238~244 (2015)
28. De Felice F, "New drug development in head and neck squamous cell carcinoma : The PI3-K inhibitors", Oral Oncol, 67, pp.119~123 (2017)
29. Laplante M, "mTOR signaling in growth control and disease", Cell, 149(2), pp.274~293 (2012)
30. Squarize CH, "PTEN deficiency contributes to the development and progression of head and neck cancer", Neoplasia, 15(5), pp.461~471 (2013)
31. Lui VW, "Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers", Cancer Discov, 3(7), pp.761~769 (2013)
32. Seiwert TY, "Integrative and comparative genomic analysis of HPVpositive and HPV-negative head and neck squamous cell carcinomas", Clin Cancer Res, 21(3), pp.632~641 (2015)
33. Chung CH, "Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing", Ann Oncol, 26(6), pp.1216~1223 (2015)
34. Soulieres D, "BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent", metastatic head and neck squamous cell carcinoma (HNSCC), 2016, pp.34(15 Suppl), 6008~
35. Zheng Y, "mTOR inhibitors at a glance", Mol Cell Pharmacol, 7(2), pp.15~20 (2015)
36. Schedel F, "mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma", Oncol Rep, 25(3), pp.763~768 (2011)
37. Chung CH, "A phase I study of everolimus in combination with cetuximab and cisplatin as first-line therapy in recurrent and metastatic (R", M) head and neck squamous cell carcinoma (HNSCC), 2012, pp.30(15 Suppl), e16061~
38. Shirai K, "A pilot, single arm, prospective trial using neoadjuvant rapamycin prior to definitive therapy in head and neck squamous cell carcinoma", J Clin Oncol, 33(15 Suppl), pp.6071~ (2015)
39. Grünwald V, "TEMHEAD: A single-arm multicentre phase II study of temsirolimus in platin-and cetuximab refractory recurrent and", or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO), 2015, pp.26(3), 561~567
40. Bauman JE, "A phase II study of temsirolimus and erlotinib in patients with recurrent and", or metastatic, platinum-refractory head and neck squamous cell carcinoma, 2013, pp.49(5), 461~467
41. Johnson DE, "Targeting the IL-6", JAK, Nat Rev Clin Oncol, pp.2018, 15(4)[DOI]
42. Cohen EE, "1135OPhase 1b", 2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN), 2017, pp.28(Suppl 5), v403~v427
43. Kyzas PA, "Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma : A meta-analysis", Clin Cancer Res, 11(4), pp.1434~1440 (2005)
44. McGee MC, "Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation", Int J Radiat Oncol Biol Phys, 76(5), pp.1537~1545 (2010)
45. Cohen EE, "Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck : A phase I", II study, 2009, pp.10(3), 247~257
46. Argiris A, "Cetuximab and bevacizumab : Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck", Ann Oncol, 24(1), pp.220~225 (2013)
47. Fury MG, "A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III", IVB head and neck squamous cell cancer, 2012, pp.118(20), 5008~5014
48. Argiris A, "Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer : An eastern cooperative oncology group trial", J Clin Oncol, 31(11), pp.1405~1414 (2013)
49. Shapiro GI, "Cyclin-dependent kinase pathways as targets for cancer treatment", J Clin Oncol, 24(11), pp.1770~1783 (2006)
50. Hamilton E, "Targeting CDK4", 6 in patients with cancer, 2016, pp.45, 129~138
51. Asghar U, "The history and future of targeting cyclin-dependent kinases in cancer therapy", Nat Rev Drug Discov, 14(2), pp.130~146 (2015)
52. Flaherty KT, "Phase I, dose-escalation trial of the oral cyclindependent kinase 4", 6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer, 2012, pp.18(2), 568~576
53. Infante JR, "A phase I study of the single-agent CDK4", 6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas, 2014, pp.32(15 Suppl), 2528~
54. Shapiro G, "A first-in-human phase I study of the CDK4", 6 inhibitor, LY2835219, for patients with advanced cance, 2013, pp.31(15 suppl), 2500~
55. Choschzick M, "Role of cyclin D1 amplification and expression in vulvar carcinomas", Hum Pathol, 43(9), pp.1386~1393 (2012)
56. Michel L, "Phase I trial of palbociclib, a selective cyclin dependent kinase 4", 6 inhibitor, in combination with cetuximab in patients with recurrent, Oral Oncol, pp.2016, 58[DOI]
57. Adkins D, "Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4", 6 inhibitor, and cetuximab in platinumresistant HPV unrelated (-) recurrent, J Clin Oncol, pp.2018, 36(15 Suppl)[DOI]
58. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12(4), pp.252~264 (2012)
59. Postow MA, "Immune checkpoint blockade in cancer therapy", J Clin Oncol, 33(17), pp.1974~1982 (2015)
60. Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373(2), pp.123~135 (2015)
61. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : A randomised controlled trial", Lancet, 387(10027), pp.1540~1550 (2016)
62. Robert C, "Nivolumab in previously untreated melanoma without BRAF mutation", N Engl J Med, 372(4), pp.320~330 (2015)
63. Duray A, "Immune suppression in head and neck cancers : A review", Clin Dev Immunol, 2010, pp.701657~ (2010)
64. Cohen EE, "LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R", M HNSCC): Phase 3 KEYNOTE-040 trial, 2017, pp.28(suppl 5), ~
65. Saba NF, "Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R", M)squamous cell carcinoma of the head and neck (SCCHN): analysis of CheckMate 141 by age, 2018, pp.36(15 suppl), 6028~
66. Seiwert TY, "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012) : An open-label, multicentre, phase 1b trial", Lancet Oncol, 17(7), pp.956~965 (2016)
67. Chow LQM, "Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and", or metastatic head and neck squamous cell carcinoma : Results from the phase Ib KEYNOTE-012 expansion cohort, 2016, pp.34(32), 3838~3845
68. Klochikhin A, "11TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent", metastatic head and neck squamous cell carcinoma: KEYNOTE-048, 2015, pp.26(suppl 8), viii5~
69. Bauml J, "Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer : Results from a single-arm, phase II study", J Clin Oncol, 35(14), pp.1542~1549 (2017)
70. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375(19), pp.1856~1867 (2016)
71. Harrington KJ, "Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck(CheckMate 141) : Health-related quality-of-life results from a randomised, phase 3 trial", Lancet Oncol, 18(8), pp.1104~1115 (2017)
72. Kiyota N, "A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141", Oral Oncol, 73, pp.138~146 (2017)
73. Cavalieri S, "Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs", Cancer Treat Rev, 65, pp.78~86 (2018)
74. Bahleda R, "1044OLong-term safety and clinical outcomes of atezolizumab in head and neck cancer: Phase Ia trial results", Ann Oncol, 28(suppl 5) (2017)
75. Zandberg DP, "Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with >25% tumor cell PD-L1 exrepssion who have progressed on platinum-based chemotherapy", Eur J Cancer, 107, pp.142~152 (2019)
76. Alfieri S, "Immunotherapy for recurrent", metastatic head and neck cancer, 2018, pp.26(2), 152~156
77. Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373, pp.23~34 (2015)
78. Aspeslagh S, "Rationale for anti-OX40 cancer immunotherapy", Eur J Cancer, 52, pp.50~66 (2016)
79. Schaer DA, "GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability", Cancer Immunol Res, 1(5), pp.320~331 (2013)
80. Fisher TS, "Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity", Cancer Immunol Immunother, 61(10), pp.1721~1733 (2012)
81. Mahoney KM, "Combination cancer immunotherapy and new immunomodulatory targets", Nat Rev Drug Discov, 14(8), pp.561~584 (2015)
82. Chow LQM, "Phase Ib trial of the toll-like receptor 8 agonist, motolimod(VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN", Clin Cancer Res, 23(10), pp.2442~2450 (2017)
83. Massarelli E, "Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer : A phase 2 clinical trial", JAMA Oncol, 5(1), pp.67~73 (2019)
84. Tan YS, "Engineering vaccines to reprogram immunity against head and neck cancer", J Dent Res, 97(6), pp.627~634 (2018)
85. Yonesaka K, "Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab", Sci Transl Med, 3(99), pp.99 ra86~ (2011)
86. Rebucci M, "Mechanisms underlying resistance to cetuximab in the HNSCC cell line : Role of AKT inhibition in bypassing this resistance", Int J Oncol, 38(1), pp.189~200 (2011)
87. Topalian SL, "Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy", Nat Rev Cancer, 16(5), pp.275~287 (2016)
88. Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9, pp.162~174 (2009)
89. Davis RJ, "Overcoming barriers to effective immunotherapy : MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer", Oral Oncol, 58, pp.59~70 (2016)
90. Park B, "The effect of radiation on the immune response to cancers", Int J Mol Sci, 15(1), pp.927~943 (2014)
91. Uppaluri R, "Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC)", J Clin Oncol, 35(15 Suppl), pp.6012~ (2017)
92. Ferris R, "LBA46An open-label, multicohort, phase 1", 2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN), 2017, pp.28(suppl 5), ~

관련 논문AI추천